|
1
|
Ostrom QT, Gittleman H, Truitt G, Boscia
A, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report:
Primary brain and other central nervous system tumors. Diagnosed in
the United States in 2011–2015. Neuro Oncol. 20 (Suppl_4):iv1–iv86.
2018. View Article : Google Scholar
|
|
2
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 world health organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 13:803–820. 2016. View Article : Google Scholar
|
|
3
|
Wisoff JH, Sanford RA, Heier LA, Sposto R,
Burger PC, Yates AJ, Holmes EJ and Kun LE: Primary neurosurgery for
pediatric low-grade gliomas: A prospective multi-institutional
study from the children's oncology group. Neurosurgery.
68:1548–1554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ryall S, Tabori U and Hawkins C: Pediatric
low-grade glioma in the era of molecular diagnostics. Acta
Neuropathol Commun. 8:302020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kandels D, Pietsch T, Bison B,
Warmuth-Metz M, Thomale UW, Kortmann RD, Timmermann B, Driever PH,
Witt O, Schmidt R and Gnekow AK: Loss of efficacy of subsequent
nonsurgical therapy after primary treatment failure in pediatric
low-grade glioma patients-report from the german siop-lgg 2004
cohort. Int J Cancer. 147:3471–3489. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stokland T, Liu JF, Ironside JW, Ellison
DW, Taylor R, Robinson KJ, Picton SV and Walker DA: A multivariate
analysis of factors determining tumor progression in. Childhood
low-grade glioma: A population-based cohort study (CCLG CNS9702).
Neuro Oncol. 12:1257–1268. 2010.
|
|
7
|
Campen CJ and Gutmann DH: Optic pathway
gliomas in neurofibromatosis type 1. J Child Neurol. 33:73–81.
2018. View Article : Google Scholar
|
|
8
|
Moorman B, Barbour M and Huang MA: Current
salvage treatment strategies for younger children (<10 y of Age)
with progressive low-grade glioma after initial chemotherapy in
north america: A web-based survey. J Pediatr Hematol Oncol.
43:e141–e145. 2021. View Article : Google Scholar
|
|
9
|
Ater JL, Zhou T, Holmes E, Mazewski CM,
Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, Sposto R, et
al: Randomized study of two chemotherapy regimens for treatment of
low-grade glioma in young children: A report from the children's
oncology group. J Clin Oncol. 30:2641–2647. 2012. View Article : Google Scholar
|
|
10
|
Karnofsky DA and Burchenal JH: The
clinical evaluation of chemotherapeutic agents in cancer.
Evaluation of Chemotherapeutic Agents. MacLeod CM: Columbia
University Press; New York, NY: pp. 191–205. 1949
|
|
11
|
Colenbrander A: Visual Standards aspects
and ranges of vision loss with emphasis on population surveys.
Proceedings of the 29th International Congress of Ophthalmology;
Sydney: 2002
|
|
12
|
Fangusaro J, Witt O, Driever PH, Bag AK,
de Blank P, Kadom N, Kilburn L, Lober RM, Robison NJ, Fisher MJ, et
al: Response assessment in pediatric low-grade glioma:
Recommendations from the response assessment in pediatric
neuro-oncology (RAPNO) working group. Lancet Oncol. 21:e305–e316.
2020. View Article : Google Scholar
|
|
13
|
National Cancer Institute (NIH), . Common
Terminology Criteria for Adverse Events (CTCAE). Version 4. NIH;
Bethesda, MD: 2010, https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v4June
14–2010
|
|
14
|
Scheinemann K, Bartels U, Tsangaris E,
Hawkins C, Huang A, Dirks P, Fried I, Bouffet E and Tabori U:
Feasibility and efficacy of repeated chemotherapy for progressive
pediatric low-grade gliomas. Pediatr Blood Cancer. 57:84–88. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bouffet E, Hargrave D, Cairney E, Garre M,
Slavc I and Baruchel S: Weekly vinblastine for
recurrent/progressive low-grade gliomas. Proceedings of
International Society of Paediatric Oncology SIOP XXXIV Meeting.
Porto; pp. p2152002
|
|
16
|
Gururangan S, Cavazos CM, Ashley D,
Herndon JE II, Bruggers CS, Moghrabi A, Scarcella DL, Watral M,
Tourt-Uhlig S, Reardon D and Friedman HS: Phase II study of
carboplatin in children with progressive low-grade gliomas. J Clin
Oncol. 20:2951–2958. 2002. View Article : Google Scholar
|
|
17
|
Ater JL, Xia C, Mazewski CM, Booth TN,
Freyer DR, Packer RJ, Sposto R, Vezina G and Pollack IF:
Nonrandomized comparison of neurofibromatosis type 1 and
non-neurofibromatosis type 1 children who received carboplatin and
vincristine for progressive low-grade glioma: A report from the
children's oncology group. Cancer. 122:1928–1936. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stucklin ASG, Ryall S, Fukuoka K,
Zapotocky M, Lassaletta A, Li C, Bridge T, Kim B, Arnoldo A,
Kowalski PE, et al: Alterations in ALK/ROS1/NTRK/MET drive a group
of infantile hemispheric gliomas. Nat Commun. 10:43432019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Manoharan N, Choi J, Chordas C, Zimmerman
MA, Scully J, Clymer J, Filbin M, Ullrich NJ, Bandopadhayay P, Chi
SN and Yeo KK: Trametinib for the treatment of
recurrent/progressive pediatric low-grade glioma. J Neurooncol.
149:253–262. 2020. View Article : Google Scholar
|
|
20
|
Packer RJ, Lange B, Ater J, Nicholson HS,
Allen J, Walker R, Prados M, Jakacki R, Reaman G, Needles MN, et
al: Carboplatin and vincristine for recurrent and newly diagnosed
low-grade gliomas of childhood. J Clin Oncol. 11:850–856. 1993.
View Article : Google Scholar
|
|
21
|
Dodgshun AJ, Maixner WJ, Heath JA,
Sullivan MJ and Hansford JR: Single-agent carboplatin for pediatric
low-grade glioma: A retrospective analysis shows equivalent
efficacy to multi-agent chemotherapy. Int J Cancer. 138:481–488.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bouffet E, Jakacki R, Goldman S, Hargrave
D, Hawkins C, Shroff M, Hukin J, Bartels U, Foreman N, Kellie S, et
al: Phase II study of weekly vinblastine in recurrent, refractory
pediatric low-grade glioma. J Clin Oncol. 30:1358–1363. 2012.
View Article : Google Scholar
|
|
23
|
Shofty B, Ben-Sira L, Freedman S, Yalon M,
Dvir R, Weintraub M, Toledano H, Constantini S and Kesler A: Visual
outcome following chemotherapy for progressive optic pathway
gliomas. Pediatr Blood Cancer. 57:481–485. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
de Haas V, Grill J, Raquin MA, Couanet D,
Habrand JL, Sainte-Rose C, Laithier V, Kieffer V and Kalifa C:
Relapses of optic pathway tumors after first-line chemotherapy.
Pediatr Blood Cancer. 52:575–580. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lassaletta A, Scheinemann K, Zelcer SM,
Hukin J, Wilson BA, Jabado N, Carret AS, Lafay-Cousin L, Larouche
V, Hawkins CE, et al: Phase II weekly vinblastine for
chemotherapy-na¨ive children with progressive low-grade glioma: A
Canadian pediatric brain tumor consortium study. J Clin Oncol.
34:3537–3543. 2016. View Article : Google Scholar
|
|
26
|
Ullrich NJ, Prabhu SP, Packer RJ, Goldman
S, Robison NJ, Allen JC, Viskochil DH, Gutmann DH, Perentesis JP,
Korf BR, et al: Visual outcomes following everolimus targeted
therapy for neurofibromatosis type 1-associated optic pathway
gliomas in children. Pediatric Blood Cancer. 68:e288332021.
View Article : Google Scholar : PubMed/NCBI
|
